Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

21.25
-3.5250-14.23%
Post-market: 21.550.3000+1.41%16:23 EDT
Volume:141.89K
Turnover:3.10M
Market Cap:495.28M
PE:-0.93
High:25.48
Open:24.78
Low:20.89
Close:24.78
52wk High:45.00
52wk Low:7.65
Shares:23.31M
Float Shares:14.16M
Volume Ratio:1.12
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.7500
EPS(LYR):-26.2348
ROE:-86.98%
ROA:-30.33%
PB:2.00
PE(LYR):-0.81

Loading ...

Lyell Immunopharma Q4 EPS $(7.68) Misses $(2.55) Estimate, Sales $6.000K Miss $20.330K Estimate

Benzinga
·
Mar 13

Lyell Immunopharma Initiated at Market Outperform by Citizens

Dow Jones
·
Mar 09

Lyell Immunopharma: Appointment of Smital Shah as Chief Financial & Business Officer, Principal Financial Officer

THOMSON REUTERS
·
Mar 09

Lyell Immunopharma appoints Smital Shah as Chief Financial and Business Officer

Reuters
·
Mar 09

Press Release: Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Dow Jones
·
Mar 09

Lyell Immunopharma initiated with an Outperform at Citizens

TIPRANKS
·
Mar 09

Lyell Immunopharma Inc expected to post a loss of $2.37 a share - Earnings Preview

Reuters
·
Mar 07

Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know

TIPRANKS
·
Feb 28

Keros Therapeutics Adds Veteran Finance Leader to Board

TIPRANKS
·
Feb 27

Lyell Immunopharma Announces Participation in March Investor Conferences

GlobeNewswire
·
Feb 23

Lyell Immunopharma Launches Phase 3 Trial Comparing Ronde-cel to Approved CAR T Therapies in Large B-Cell Lymphoma

Reuters
·
Feb 12

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-to-Head Car T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

THOMSON REUTERS
·
Feb 12

Lyell Immunopharma Inc - Bla Submission Expected in 2027

THOMSON REUTERS
·
Feb 12

Lyell Immunopharma VP Veronica Sanchez Bulis Reports Sale of Common Shares

Reuters
·
Jan 07

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:04 PM

Reuters
·
Dec 23, 2025

Lyell Immunopharma Shares Rise After HC Wainwright Upgrade

MT Newswires Live
·
Dec 10, 2025

BUZZ-H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression

Reuters
·
Dec 09, 2025

Lyell Immunopharma Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
Dec 09, 2025

HC Wainwright Upgrades Lyell Immunopharma to Buy From Neutral, Adjusts PT to $45 From $20

MT Newswires Live
·
Dec 09, 2025

Lyell Immunopharma Inc : H.c. Wainwright Raises to Buy From Neutral; Raises Target Price to $45 From $20

THOMSON REUTERS
·
Dec 09, 2025